Gilead Cashing In On Hepatitis C Cure

July 24, 2014 9:48 AM

93 0

San Francisco-based Gilead Sciences Inc. has seen its second quarter results benefit from sales of Sovaldi – to the tune of $5.8 billion.

The launch of Sovaldi, a treatment for Hepatitis C with a claimed cure rate of 90% and fewer side effects than previously available treatments, was highly anticipated by patients and medical professionals alike. Flags have been raised, however, at the high price tag – $1000 per pill, making the 12 w...

Read more

To category page